Conclusion:
This study of the first 20 patients prescribed selexipag in our centre
demonstrates that selexipag can be safely initiated, titrated and
transitioned in an outpatient setting to achieve an individualised
dosing regimen. Prostacyclin side effects were common, but improved in
the maintenance phase. There were no drug discontinuations or deaths in
this study, but close observation and consideration of clinical,
biochemical and hemodynamic parameters are recommended following any
changes in drug therapy.
References :
1. Lang IM and Gaine SP. Recent
advances in targeting the prostacyclin pathway in pulmonary arterial
hypertension. Eur Respir Rev 2015; 24: 630-641. 2015/12/02. DOI:
10.1183/16000617.0067-2015.
2. Galie N, Humbert M, Vachiery JL, et
al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary
hypertension: The Joint Task Force for the Diagnosis and Treatment of
Pulmonary Hypertension of the European Society of Cardiology (ESC) and
the European Respiratory Society (ERS): Endorsed by: Association for
European Paediatric and Congenital Cardiology (AEPC), International
Society for Heart and Lung Transplantation (ISHLT). The European
respiratory journal 2015; 46: 903-975. 2015/09/01. DOI:
10.1183/13993003.01032-2015.
3. Rajkumar R, Konishi K, Richards TJ,
et al. Genomewide RNA expression profiling in lung identifies distinct
signatures in idiopathic pulmonary arterial hypertension and secondary
pulmonary hypertension. Am J Physiol Heart Circ Physiol 2010;
298: H1235-H1248. 2010/01/15. DOI: 10.1152/ajpheart.00254.2009.
4. Menyhart K and Nayler O. Influence
of IP Receptor Density on Agonist Activity of ACT-333679, the Active
Metabolite of Selexipag. A66 PH: MOLECULES, CELLS AND ANIMAL
MODELS . pp.A2239-A2239.
5. Farber HW and Gin-Sing W. Practical
considerations for therapies targeting the prostacyclin pathway.European Respiratory Review 2016; 25: 418-430. DOI:
10.1183/16000617.0083-2016.
6. Sitbon O, Channick R, Chin KM, et
al. Selexipag for the Treatment of Pulmonary Arterial Hypertension.New England Journal of Medicine 2015; 373: 2522-2533. DOI:
10.1056/NEJMoa1503184.
7. Simonneau G, Torbicki A, Hoeper MM,
et al. Selexipag: an oral, selective prostacyclin receptor agonist for
the treatment of pulmonary arterial hypertension. European
Respiratory Journal 2012; 40: 874-880. DOI: 10.1183/09031936.00137511.
8. Gomberg-Maitland M and Olschewski
H. Prostacyclin therapies for the treatment of pulmonary arterial
hypertension. European Respiratory Journal 2008; 31: 891-901.
DOI: 10.1183/09031936.00097107.
9. Surveillance for respiratory
hazards in the occupational setting [American Thoracic Society].Am Rev Respir Dis 1982; 126: 952-956. 1982/11/01.
10. Kingman M, Archer-Chicko C,
Bartlett M, et al. Management of prostacyclin side effects in adult
patients with pulmonary arterial hypertension. Pulm Circ 2017; 7:
598-608. 2017/07/11. DOI: 10.1177/2045893217719250.
11. Galiè N, Barberà JA, Frost AE, et
al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial
Hypertension. New England Journal of Medicine 2015; 373: 834-844.
DOI: 10.1056/NEJMoa1413687.
12. Sitbon O and Gaine S. Beyond a
single pathway: combination therapy in pulmonary arterial hypertension.European Respiratory Review 2016; 25: 408-417. DOI:
10.1183/16000617.0085-2016.
13. Sofer A, Ryan MJ, Tedford RJ, et
al. A systematic review of transition studies of pulmonary arterial
hypertension specific medications. Pulm Circ 2017; 7: 326-338.
2017/06/10. DOI: 10.1177/2045893217706357.
14. Chakinala MM, Feldman JP,
Rischard F, et al. Transition from parenteral to oral treprostinil in
pulmonary arterial hypertension. J Heart Lung Transplant 2017;
36: 193-201. 2016/07/30. DOI: 10.1016/j.healun.2016.06.019.
15. Frost A, Janmohamed M, Fritz JS,
et al. Safety and tolerability of transition from inhaled treprostinil
to oral selexipag in pulmonary arterial hypertension: Results from the
TRANSIT-1 study. J Heart Lung Transplant 2019; 38: 43-50.
2018/11/06. DOI: 10.1016/j.healun.2018.09.003.
16. Yanaka K, Guillien A, Soumagne T,
et al. Transition from intravenous epoprostenol to selexipag in
pulmonary arterial hypertension: a word of caution. European
Respiratory Journal 2020; 55: 1902418. DOI:
10.1183/13993003.02418-2019.
17. Pan IZ, Carey JR, Jacobs JA, et
al. Transitioning Between Prostanoid Therapies in Pulmonary Arterial
Hypertension. Front Med (Lausanne) 2020; 7: 81-81. DOI:
10.3389/fmed.2020.00081.
18. Bhura S and Gibbons W.
TRANSITIONING FROM INHALED ILOPROST TO ORAL SELEXIPAG: A CASE REPORT.Chest 2019; 156: A741. DOI: 10.1016/j.chest.2019.08.714.
19. Olschewski H, Simonneau G, Galiè
N, et al. Inhaled Iloprost for Severe Pulmonary Hypertension. New
England Journal of Medicine 2002; 347: 322-329. DOI:
10.1056/NEJMoa020204.
20. Nakayama K, Emoto N, Tamada N, et
al. The optimization of iloprost inhalation under moderate flow of
oxygen therapy in severe pulmonary arterial hypertension. Pulm
Circ 2018; 8: 2045894018781537-2045894018781537. 2018/05/21. DOI:
10.1177/2045894018781537.
21. Gaine S, Sitbon O, Channick RN,
et al. The Impact of Time from Diagnosis at Baseline on Long-Term
Outcome in the GRIPHON Study: Selexipag in Pulmonary Arterial
Hypertension. A105 GLORY DAYS: THE LATEST CLINICAL RESEARCH IN
PAH . pp.A2502-A2502.
22. Holthaus N, Prins K, Rose L, et
al. EXPRESS: Transition from Parental Prostacyclin to Selexipag: A Case
Series of Five Pulmonary Arterial Hypertension Patients. Pulm
Circ 2019: 2045894019862167. 2019/06/20. DOI: 10.1177/2045894019862167.
23. McLaughlin VV, Channick R, De
Marco T, et al. Results of an Expert Consensus Survey on the Treatment
of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway
Agents. Chest 2020; 157: 955-965. 2019/11/19. DOI:
10.1016/j.chest.2019.10.043.
24. Hardin EA and Chin KM. Selexipag
in the treatment of pulmonary arterial hypertension: design,
development, and therapy. Drug Des Devel Ther 2016; 10:
3747-3754. DOI: 10.2147/DDDT.S103534.
25. Gatfield J, Menyhart K, Wanner D,
et al. Selexipag Active Metabolite ACT-333679 Displays Strong
Anticontractile and Antiremodeling Effects but Low β-Arrestin
Recruitment and Desensitization Potential. J Pharmacol Exp Ther2017; 362: 186-199. 2017/05/10. DOI: 10.1124/jpet.116.239665.